Compatibilidad
Ahorrar(0)
Publications & Major Posters on PARP by NMS
| 2025 | L. Mahnke Exploring Next-Gen PARP Inhibitors without PARP Trapping – 8th Annual DDR Inhibitors Summit,January 28-30, 2025, Boston . | |
| 2023 | Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitor. Mol Cancer Ther (2023) 22 (12_Supplement): LB_A12.POSTER: Geurts M. et al., Initial Results from 2 PhaseI Studies of NMS-03305293, a Selective PARP-1 Inhibitor |
|
| 2019 | Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515. ACS Med. Chem. Lett. 2019, 10, 4, 534–538 |
|
| 2018 | NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma. Proceedings of the American Association for Cancer Research Annual Meeting; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4843. |
|
| 2016 | NMS-P293, a novel potent and selective PARP-1 inhibitor with high antitumor efficacy and tolerability. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1223. |
|
| 2015 | Nuovi bersagli oncologici: PARP. La Chimica e l’industria 2015, 97, 24-27. |
|
| 2015 | Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. J. Med. Chem. 2015, 58, 17, 6875–6898 |
|
| 2015 | Preclinical characterization of NMS-P648, a novel and potent PARP-1/-3 inhibitor. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2851. |
|
| 2014 | Insights into PARP Inhibitors’ Selectivity Using Fluorescence Polarization and Surface Plasmon Resonance Binding Assays. Journal of Biomolecular Screening. 2014;19(8):1212-1219. |
|
| 2013 | PARP inhibitors in cancer therapy: an update. Expert Opinion on Therapeutic Patents, 2013, 23(4), 503–514. |
|
| 2013 | Novel isoquinolinone derivatives with dual PARP-1/PARP-3 inhibitory activity are highly active against pTEN mutated colorectal cancer and glioblastoma models. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3259. |
|
| 2012 | Characterization of new highly selective and potent PARP-1 inhibitors. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1775. |
|
| 2011 | Identification of candidate substrates for poly(ADP-ribose)polymerase-2 (PARP2) in the absence of DNA damage using high-density protein microarrays. FEBS Journal 278(2011) 3676–3687 |
|
| 2010 | In vitro and in vivo characterization of selective orally available Parp-1 inhibitors with demonstrated antitumor efficacy in BRCA negative cancer models. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 691. |
|
| 2009 | Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? Expert Opinion on Therapeutic Patents, 2009, 19(10), 1377–1400. |
Other references
NMS Group
